Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

STAT reporters discuss why a looming patent cliff could lead to more pharmaceutical deal-making and a new obesity startup.

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.At the Cardiometabolic Health Congress in ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

Elderberry juice rich in anthocyanins boosts glucose regulation and fat metabolism, with significant effects on gut ...

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...

The negative impact of obesity on prognosis was especially pronounced in patients with acute lymphoblastic leukemia and brain ...

Although bipartisan legislation to provide Medicare coverage for obesity treatments has circulated in Congress for more than ...

"Alison was the preeminent scholar on adolescent obesity and eating disorders,” said Kerri Boutelle, a pediatrics professor ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Breaking the silence on how generational trauma impacts obesity in Black communities, through one woman's powerful journey ...